AnaptysBio Financial Statements From 2010 to 2025

ANAB Stock  USD 17.42  0.62  3.44%   
AnaptysBio financial statements provide useful quarterly and yearly information to potential AnaptysBio investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on AnaptysBio financial statements helps investors assess AnaptysBio's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting AnaptysBio's valuation are summarized below:
Gross Profit
-97.6 M
Profit Margin
(2.90)
Market Capitalization
530.1 M
Enterprise Value Revenue
2.0367
Revenue
57.2 M
We have found one hundred twenty available fundamental signals for AnaptysBio, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of AnaptysBio prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road.

AnaptysBio Total Revenue

24.42 Million

Check AnaptysBio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AnaptysBio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Interest Expense of 21.8 M or Selling General Administrative of 50.6 M, as well as many indicators such as Price To Sales Ratio of 36.72, Dividend Yield of 0.0 or PTB Ratio of 7.15. AnaptysBio financial statements analysis is a perfect complement when working with AnaptysBio Valuation or Volatility modules.
  
Check out the analysis of AnaptysBio Correlation against competitors.
For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.

AnaptysBio Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets354.3 M520.2 M276.9 M
Slightly volatile
Short and Long Term Debt Total10.8 M20.5 M8.9 M
Slightly volatile
Other Current Liabilities37.4 M35.6 M9.9 M
Slightly volatile
Total Current Liabilities45.2 M43.1 M18.2 M
Slightly volatile
Total Stockholder Equity96.3 M101.3 M161.8 M
Slightly volatile
Property Plant And Equipment Net22.1 M21 M7.1 M
Slightly volatile
Current Deferred Revenue6.5 M11.7 M6.5 M
Slightly volatile
Accounts Payable4.2 M5.4 M3.3 M
Slightly volatile
Cash39.3 M41.4 M89.8 M
Slightly volatile
Non Current Assets Total53.5 M52.4 M40.2 M
Slightly volatile
Non Currrent Assets Other218.9 K230.4 K626.6 K
Very volatile
Cash And Short Term Investments295.2 M449.5 M231.5 M
Slightly volatile
Common Stock Total Equity22.2 K33.4 K21.1 K
Slightly volatile
Common Stock Shares Outstanding21 M24.2 M32.1 M
Slightly volatile
Liabilities And Stockholders Equity354.3 M520.2 M276.9 M
Slightly volatile
Non Current Liabilities Total394.7 M375.9 M108.6 M
Slightly volatile
Other Current Assets11 M10.4 M3.9 M
Slightly volatile
Other Stockholder Equity848.8 M808.4 M309.1 M
Slightly volatile
Total Liabilities439.9 M418.9 M126.5 M
Slightly volatile
Property Plant And Equipment Gross29.6 M28.2 M8.4 M
Slightly volatile
Total Current Assets300.8 M467.9 M236.6 M
Slightly volatile
Short Term Debt2.6 MM2.1 M
Slightly volatile
Common Stock22.9 K31.1 K20.9 K
Slightly volatile
Other Liabilities367.6 M350.1 M115.2 M
Slightly volatile
Other Assets279.7 K294.4 K1.6 M
Pretty Stable
Long Term Debt534.4 K562.5 K3.4 M
Slightly volatile
Short and Long Term Debt1.2 M1.2 M4.2 M
Slightly volatile
Property Plant Equipment1.6 M2.4 M1.3 M
Slightly volatile
Long Term Debt Total534.4 K562.5 K3.5 M
Slightly volatile
Capital Surpluse517.6 M825.5 M368.9 M
Slightly volatile
Short Term Investments252.1 M408.2 M214.7 M
Slightly volatile
Capital Lease Obligations21.5 M20.5 M6.4 M
Slightly volatile
Net Invested Capital75.3 M79.3 M295.9 M
Slightly volatile
Long Term Investments29.5 M31.1 M65.6 M
Slightly volatile
Non Current Liabilities Other375.3 M357.4 M115.8 M
Slightly volatile
Net Working Capital425 M424.8 M326.5 M
Slightly volatile
Capital Stock30.2 K31.1 K27.6 K
Slightly volatile

AnaptysBio Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And AmortizationM2.7 M1.7 M
Slightly volatile
Interest Expense21.8 M20.8 M6.1 M
Slightly volatile
Selling General Administrative50.6 M48.2 M17.3 M
Slightly volatile
Total Revenue24.4 M19.7 M19 M
Slightly volatile
Other Operating Expenses219.2 M208.8 M79.7 M
Slightly volatile
Research Development159.7 M152.1 M60.8 M
Slightly volatile
Total Operating Expenses219.2 M208.8 M79.7 M
Slightly volatile
Cost Of Revenue2.6 M2.7 M28.7 M
Pretty Stable
Interest Income21.5 M20.5 M6.4 M
Slightly volatile
Reconciled Depreciation2.9 M2.7 M953.8 K
Slightly volatile

AnaptysBio Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation40.1 M38.2 M12.2 M
Slightly volatile
Begin Period Cash Flow131.8 M82 M97 M
Slightly volatile
Depreciation2.9 M2.7 M1.1 M
Slightly volatile
Other Non Cash Items9.1 M8.7 M3.3 M
Slightly volatile
Capital Expenditures572.8 K928 K458.7 K
Slightly volatile
End Period Cash Flow39.3 M41.4 M89.8 M
Slightly volatile
Change Receivables980 K1.1 M1.2 M
Slightly volatile
Cash Flows Other Operating31.6 M30.1 M10.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio36.7238.6697.3946
Slightly volatile
PTB Ratio7.157.531.7 K
Slightly volatile
Days Sales Outstanding13813153.8335
Slightly volatile
Book Value Per Share2.82.956.3543
Slightly volatile
Stock Based Compensation To Revenue1.831.740.7979
Slightly volatile
Capex To Depreciation0.290.310.6937
Pretty Stable
PB Ratio7.157.531.7 K
Slightly volatile
EV To Sales35.5737.4492.6745
Slightly volatile
Days Of Inventory On Hand1.0E-41.0E-40.0
Slightly volatile
Payables Turnover0.550.5820.3207
Slightly volatile
Sales General And Administrative To Revenue2.312.21.1995
Slightly volatile
Average Inventory0.40.450.4906
Slightly volatile
Research And Ddevelopement To Revenue3.616.944.0629
Slightly volatile
Capex To Revenue0.03540.04230.0365
Slightly volatile
Cash Per Share8.4613.078.6278
Slightly volatile
Days Payables Outstanding682650173
Slightly volatile
Income Quality1.410.851.2154
Slightly volatile
Current Ratio11.179.7811.0874
Slightly volatile
Tangible Book Value Per Share2.82.956.3543
Slightly volatile
Receivables Turnover2.142.2521.0849
Pretty Stable
Graham Number14.0719.0414.1731
Slightly volatile
Shareholders Equity Per Share2.82.956.3543
Slightly volatile
Debt To Equity0.220.231.7409
Slightly volatile
Capex Per Share0.01680.0270.0173
Slightly volatile
Revenue Per Share0.760.570.7525
Slightly volatile
Interest Debt Per Share1.261.20.5709
Slightly volatile
Debt To Assets0.0430.04530.1073
Slightly volatile
Operating Cycle13813153.8335
Slightly volatile
Price Book Value Ratio7.157.531.7 K
Slightly volatile
Days Of Payables Outstanding682650173
Slightly volatile
Ebt Per Ebit1.171.141.0667
Very volatile
Company Equity Multiplier4.765.98.7023
Slightly volatile
Long Term Debt To Capitalization0.00140.00150.1638
Slightly volatile
Total Debt To Capitalization0.210.190.3148
Slightly volatile
Debt Equity Ratio0.220.231.7409
Slightly volatile
Quick Ratio11.179.7811.0874
Slightly volatile
Net Income Per E B T1.11.151.0242
Slightly volatile
Cash Ratio0.820.865.4373
Pretty Stable
Days Of Inventory Outstanding1.0E-41.0E-40.0
Slightly volatile
Days Of Sales Outstanding13813153.8335
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.810.910.9935
Slightly volatile
Price To Book Ratio7.157.531.7 K
Slightly volatile
Fixed Asset Turnover1.031.0812.2419
Pretty Stable
Debt Ratio0.0430.04530.1073
Slightly volatile
Price Sales Ratio36.7238.6697.3946
Slightly volatile
Asset Turnover0.04140.04360.4558
Slightly volatile
Price Fair Value7.157.531.7 K
Slightly volatile

AnaptysBio Fundamental Market Drivers

Cash And Short Term Investments390.9 M

AnaptysBio Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About AnaptysBio Financial Statements

AnaptysBio stakeholders use historical fundamental indicators, such as AnaptysBio's revenue or net income, to determine how well the company is positioned to perform in the future. Although AnaptysBio investors may analyze each financial statement separately, they are all interrelated. For example, changes in AnaptysBio's assets and liabilities are reflected in the revenues and expenses on AnaptysBio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in AnaptysBio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue11.7 M6.5 M
Total Revenue19.7 M24.4 M
Cost Of Revenue2.7 M2.6 M
Stock Based Compensation To Revenue 1.74  1.83 
Sales General And Administrative To Revenue 2.20  2.31 
Research And Ddevelopement To Revenue 6.94  3.61 
Capex To Revenue 0.04  0.04 
Revenue Per Share 0.57  0.76 
Ebit Per Revenue(11.02)(10.47)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock:
Check out the analysis of AnaptysBio Correlation against competitors.
For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.05)
Revenue Per Share
2.086
Quarterly Revenue Growth
8.047
Return On Assets
(0.18)
Return On Equity
(1.62)
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.